Drug Pipeline

Elimusertib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
0
Recruiting
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT04491942
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy…		 date change Primary completion pushed: 2026-06-30 -> 2027-06-30
2026-06-12 NCT04491942
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy…		 date change Completion pushed: 2026-06-30 -> 2027-06-30
Active Studies by Phase
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT05071209 Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Recurrent Alveolar Rhabdomyosarcoma Active, Not Recruiting
Phase 1
NCT04514497 Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for… Metastatic Lung Small Cell Carcinoma Active, Not Recruiting
NCT04491942 Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy… Advanced Bile Duct Carcinoma Active, Not Recruiting
Sponsors Running Elimusertib Trials
National Cancer Institute (NCI) (3)
Disease Areas
Small Cell Lung Cancer (2) Lung Cancer (2) Non-Small Cell Lung Cancer (NSCLC) (1) Breast Cancer (1) Gastric Cancer (1) Bladder Cancer (1) Ovarian Cancer (1) Cervical Cancer (1) Endometrial Cancer (1) Esophageal Cancer (1)
Get alerts when Elimusertib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free